Key result
Higher soluble neprilysin is linked to ~29% greater HF hospitalization risk, especially in overweight women.
Why the study?
Higher neprilysin activity has been suggested in women, motivating evaluation of how sex and body mass index influence the association between soluble neprilysin and recurrent admissions.
Does soluble neprilysin level predict heart failure hospitalizations differently based on sex and BMI in heart failure outpatients?
Observational (n=1,021)
No
Does soluble neprilysin level predict heart failure hospitalizations differently based on sex and BMI in heart failure outpatients?
Higher soluble neprilysin levels better predict an increased risk of heart failure hospitalization specifically in overweight women.
Answers are grounded in this paper and cite their sources.
sNEP may flag higher HF hospitalization risk in overweight women; hypothesis-generating and should not yet change practice.
A higher neprilysin activity has been suggested in women. In this retrospective analysis, we evaluated the association of sex and body mass index (BMI) with soluble neprilysin (sNEP) and recurrent admissions among 1021 consecutive HF outpatients. The primary and secondary endpoints were the number of HF hospitalizations and all-cause mortality, respectively. The association between sNEP with either endpoint was evaluated across sex and BMI categories (≥ 25 kg/m2 vs. < 25 kg/m2). Bivariate count regression (Poisson) was used, and risk estimates were expressed as incidence rates ratio (IRR). During a median follow-up of 6.65 years (percentile 25%-percentile 75%:2.83–10.25), 702 (68.76%) patients died, and 406 (40%) had at least 1 HF hospitalization. Median values of sNEP and BMI were 0.64 ng/mL (0.39–1.22), and 26.9 kg/m2 (24.3–30.4), respectively. Left ventricle ejection fraction was < 40% in 78.9% of patients, and 28% were women. In multivariable analysis, sNEP (main effect) was positively associated with HF hospitalizations (p = 0.001) but not with mortality (p = 0.241). The predictive value of sNEP for HF hospitalizations varied non-linearly across sex and BMI categories (p-value for interaction = 0.003), with significant and positive effect only on women with BMI ≥ 25 kg/m2 (p = 0.039). For instance, compared to men, women with sNEP of 1.22 ng/mL (percentile 75%) showed a significantly increased risk (IRRs: 1.26; 95% CI: 1.05–1.53). The interaction analysis for mortality did not support a differential prognostic effect for sNEP (p = 0.072). In conclusion, higher sNEP levels in overweight women better predicted an increased risk of HF hospitalization.
No takes yet. Share an insight, caveat, or question.
Núñez et al. (2021) conducted an observational in Heart failure (n=1,021). Soluble neprilysin (sNEP) vs. Lower sNEP levels was evaluated on Number of heart failure hospitalizations (IRR 1.29, 95% CI 1.06-1.58, p=0.013). Higher soluble neprilysin levels were associated with an increased risk of heart failure hospitalizations, with the highest risk observed in overweight women.
Synapse has enriched 10 related papers. Consider them for comparative context: